High-density lipoprotein cholesterol: Current perspective for clinicians

Angiology

Volumn 60, Issue 5, 2009, Pages 644-649

  Whayne Jr , Thomas F ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Apolipoprotein; Cholesterol; Coronary heart disease; High density lipoproteins; Laropiprant; Lipoproteins; Nicotinic acid

Indexed keywords

ALPHA TOCOPHEROL; ANACETRAPIB; ASCORBIC ACID; ATORVASTATIN; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; COLESTIPOL; FENOFIBRATE; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LAROPIPRANT; LOW DENSITY LIPOPROTEIN; MOPERONE; NICOTINIC ACID; PLACEBO; SELENIUM; SIMVASTATIN; TORCETRAPIB;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG MECHANISM; FLUSHING; HEART INFARCTION; HUMAN; MORBIDITY; MORTALITY; PROTEIN FUNCTION; REVIEW; SIDE EFFECT; UNITED STATES;

ANTILIPEMIC AGENTS; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CHOLESTEROL ESTER TRANSFER PROTEINS; CHOLESTEROL, HDL; DYSLIPIDEMIAS; FLUSHING; HUMANS; INDOLES; NIACIN; OXAZOLIDINONES; QUINOLINES; TREATMENT OUTCOME;

EID: 70350493139     PISSN: 00033197     EISSN: None     Source Type: Journal    
DOI: 10.1177/0003319709331392     Document Type: Review

References (44)

1. Castelli WP Cholesterol and lipids in the risk of coronary artery disease-the Framingham Heart Study. Can J Cardiol. 1988 ; 4 (suppl A). 5A - 10A.
2. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994 ; 344: 1383-1389.
3. Shepherd J., Cobbe SM, Ford I., et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995 ; 333: 1301-1307.
4. Downs JR, Clearfield M., Weis S., et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/ TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998 ; 279: 1615-1622.
5. Barter P., Gotto AM, LaRosa JC, et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med. 2007 ; 357: 1301-1310.
6. Keech A., Simes RJ, Barter P., et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005 ; 366: 1849-1861.
7. Manninen V., Elo MO, Frick MH, et al. Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. JAMA. 1988 ; 260: 641-651. (Pubitemid 18183862)
8. OlssonA.Short-andLong-TermHDL-CEffects.Presented at the XIV International Symposium on Drugs Affecting Lipid Metabolism, September 9-13, 2001.
9. Shah PK, Kaul S., Nilsson J., Cercek B. Exploiting the vascular protective effects of high-density lipoprotein and its apolipoproteins: an idea whose time for testing is coming, part I. Circulation. 2001 ; 104: 2376-2383. (Pubitemid 33049524)
10. Nissen SE, Tsunoda T., Tuzcu EM, et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA. 2003 ; 290: 2292-2300.
11. Smart E. ĝ€Goodĝ€™ Cholesterol May Not be Good for Diabetics. Lexington, KY: University of Kentucky News ; 2008: 7.
12. Whayne T. Evaluation and critique of state of the art dyslipidemia management in general and with a special emphasis on the Indian population. Indian Heart J. 2007 ; 59: 218-225.
13. Nissen SE, Nicholls SJ, Sipahi I., et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA. 2006 ; 295: 1556-1565.
14. Athyros VG, Mikhailidis DP, Papageorgiou AA, et al. Effect of atorvastatin on high density lipoprotein cholesterol and its relationship with coronary events: a subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study. Curr Med Res Opin. 2004 ; 20: 627-637.
15. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 1996 ; 335: 1001-1009.
16. Athyros VG, Kakafika AI, Papageorgiou AA, et al. Statin-induced increase in HDL-C and renal function in coronary heart disease patients. Open Cardiovasc Med J. 2007 ; 1: 8-14.
17. Rubins HB, Robins SJ, Collins D., et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med. 1999 ; 341: 410-418.
18. Frick MH, Elo O., Haapa K., et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med. 1987 ; 317: 1237-1245.
19. Gotto AM Jr. The new cholesterol education imperative and some comments on niacin. Am J Cardiol. 1998 ; 81: 492-494.
20. Shepherd J., Packard CJ, Patsch JR, Gotto AM Jr, Taunton OD Effects of nicotinic acid therapy on plasma high density lipoprotein subfraction distribution and composition and on apolipoprotein A metabolism. J Clin Invest. 1979 ; 63: 858-867.
21. Shepherd J., Patsch JR, Packard CJ, Gotto AM Jr. Taunton OD Dynamic properties of human high density lipoprotein apoproteins. J Lipid Res. 1978 ; 19: 383-389.
22. Carlson LA Nicotinic acid: the broad-spectrum lipid drug. A 50th anniversary review. J Intern Med. 2005 ; 258: 94-114.
23. Canner PL, Furberg CD, McGovern ME Benefits of niacin in patients with versus without the metabolic syndrome and healed myocardial infarction (from the Coronary Drug Project). Am J Cardiol. 2006 ; 97: 477-479.
24. Blankenhorn DH, Selzer RH, Mack WJ, et al. Evaluation of colestipol/niacin therapy with computer-derived coronary end point measures. A comparison of different measures of treatment effect. Circulation. 1992 ; 86: 1701-1709.
25. Blankenhorn DH, Nessim SA, Johnson RL, Sanmarco ME, Azen SP, Cashin-Hemphill L. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA. 1987 ; 257: 3233-3240.
26. Brown BG, Zambon A., Poulin D., et al. Use of niacin, statins, and resins in patients with combined hyperlipidemia. Am J Cardiol. 1998 ; 81: 52B - 59B.
27. Brown G., Albers JJ, Fisher LD, et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med. 1990 ; 323: 1289-1298.
28. Brown BG, Zhao XQ, Chait A., et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med. 2001 ; 345: 1583-1592.
29. Brown BG 1-Year Event-free Survival Post-DES: Low vs. High HDL at Baseline. The Next Frontier in CV Risk Reduction. Hilton, New York ; 2007.
30. Taylor AJ, Sullenberger LE, Lee HJ, Lee JK, Grace KA Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind,placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation. 2004 ; 110: 3512-3517.
31. Pike NB Flushing out the role of GPR109A (HM74A) in the clinical efficacy of nicotinic acid. J Clin Invest. 2005 ; 115: 3400-3403.
32. Benyo Z., Gille A., Bennett CL, Clausen BE, Offermanns S. Nicotinic acid-induced flushing is mediated by activation of epidermal langerhans cells. Mol Pharmacol. 2006 ; 70: 1844-1849.
33. Morrow JD, Awad JA, Oates JA, Roberts LJ II. Identification of skin as a major site of prostaglandin D2 release following oral administration of niacin in humans. J Invest Dermatol. 1992 ; 98: 812-815.
34. Cheng K., Wu TJ, Wu KK, et al. Antagonism of the prostaglandin D2 receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humans. Proc Natl Acad Sci U S A. 2006 ; 103: 6682-6687.
35. Lai E., De Lepeleire I., Crumley TM, et al. Suppression of niacin-induced vasodilation with an antagonist to prostaglandin D2 receptor subtype 1. Clin Pharmacol Ther. 2007 ; 81: 849-857.
36. Merck Shares in Tailspin After FDA Rejects Drug. San Francisco, CA: MarketWatch ; April 29, 2008.
37. Merck Tumbles After FDA Rejects Drug. TheStreet.com. April 29, 2008.
38. Maccubbin D. Extended-release niacin plus laropiprant significantly improves lipid profile. European Society of Cardiology. Oral presentation ; September 1-5, 2007 ; Vienna, Austria.
39. Brousseau ME, Schaefer EJ, Wolfe ML, et al. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N Engl J Med. 2004 ; 350: 1505-1515.
40. Avorn J. Torcetrapib and atorvastatin-should marketing drive the research agenda ? N Engl J Med. 2005 ; 352: 2573-2576.
41. Pfizer Ends Development of Key Cholesterol Drug. CNNMoney.com. December 3, 2006.
42. Barter PJ, Caulfield M., Eriksson M., et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007 ; 357: 2109-2122.
43. Koroneos G. PharmExec.com. Risky cholesterol drug proves positive for Roche. Available at: http://pharmexec.findpharma.com/pharmexec/News/Risky- Cholesterol-DrugProves-Positive-for-Roche/ArticleStandard/Article/detail/507004? contextCategoryId=39724. April 2, 2008.
44. Bloomfield D., Carlson GL, Sapre A., et al. Anacetrapib. Presented at the XVI Symposium on Drugs Affecting Lipid Metabolism, New York, NY, October 4-7, 2007.